A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

Two genes were shown to be significantly associated with higher prevalence of myasthenia gravis (MG), a relatively rare autoimmune disease.

The investigational monoclonal antibody nipocalimab is associated with significant improvement in patients with generalized ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...

Investigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III Vivacity-MG3 ...

Myasthenia gravis (MG) is an antibody-mediated chronic neuromuscular disorder leading to fluctuating weakness and early muscle fatigue, with limited treatment options available. In MG, such as other ...

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...

Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized ...

Amgen said it achieved positive results from a Phase 3 trial of its treatment for adults with generalized myasthenia gravis, a rare autoimmune disorder.

Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults ...

Immunovant, Inc. shifts focus to anti-FcRn antibody IMVT-1402, but high R&D costs and uncertainty warrant caution for ...